SG11201508231UA - Novel bispecific binding molecules with antitumoral activity - Google Patents

Novel bispecific binding molecules with antitumoral activity

Info

Publication number
SG11201508231UA
SG11201508231UA SG11201508231UA SG11201508231UA SG11201508231UA SG 11201508231U A SG11201508231U A SG 11201508231UA SG 11201508231U A SG11201508231U A SG 11201508231UA SG 11201508231U A SG11201508231U A SG 11201508231UA SG 11201508231U A SG11201508231U A SG 11201508231UA
Authority
SG
Singapore
Prior art keywords
binding molecules
bispecific binding
antitumoral activity
novel bispecific
novel
Prior art date
Application number
SG11201508231UA
Inventor
Fabian Buller
Ulrich Wüllner
Kristina Klupsch
Irene Zbinden
Roger Santimaria
Isabella Attinger-Toller
Susann König-Friedrich
Julian Bertschinger
Dragan Grabulovski
Simon Brack
Michela Silacci
Richard Woods
Helen Hachemi
Patricia Henne
Der Bey Ulrike Von
Original Assignee
Covagen Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Covagen Ag filed Critical Covagen Ag
Publication of SG11201508231UA publication Critical patent/SG11201508231UA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C12Y207/10002—Non-specific protein-tyrosine kinase (2.7.10.2), i.e. spleen tyrosine kinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
SG11201508231UA 2013-04-19 2014-03-06 Novel bispecific binding molecules with antitumoral activity SG11201508231UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13164555 2013-04-19
PCT/EP2014/054390 WO2014170063A1 (en) 2013-04-19 2014-03-06 Novel bispecific binding molecules with antitumoral activity

Publications (1)

Publication Number Publication Date
SG11201508231UA true SG11201508231UA (en) 2015-11-27

Family

ID=48128216

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201508231UA SG11201508231UA (en) 2013-04-19 2014-03-06 Novel bispecific binding molecules with antitumoral activity

Country Status (15)

Country Link
EP (1) EP2986630B1 (en)
JP (2) JP6694808B2 (en)
KR (1) KR20160002882A (en)
CN (1) CN105189544A (en)
AU (1) AU2014256037B2 (en)
BR (1) BR112015026143A2 (en)
CA (1) CA2908988A1 (en)
CL (1) CL2015003085A1 (en)
EA (1) EA201592006A1 (en)
HK (1) HK1214605A1 (en)
MX (1) MX2015014608A (en)
PH (1) PH12015502278A1 (en)
SG (1) SG11201508231UA (en)
WO (1) WO2014170063A1 (en)
ZA (1) ZA201507752B (en)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
LT3176170T (en) 2012-06-13 2019-04-25 Incyte Holdings Corporation Substituted tricyclic compounds as fgfr inhibitors
DK2986610T5 (en) 2013-04-19 2018-12-10 Incyte Holdings Corp BICYCLIC HETEROCYCLES AS FGFR INHIBITORS
IL302303A (en) 2013-12-17 2023-06-01 Genentech Inc Anti-cd3 antibodies and methods of use
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
CN107438607B (en) 2015-02-20 2021-02-05 因赛特公司 Bicyclic heterocycles as FGFR inhibitors
MA41551A (en) 2015-02-20 2017-12-26 Incyte Corp BICYCLIC HETEROCYCLES USED AS FGFR4 INHIBITORS
WO2016204966A1 (en) 2015-06-16 2016-12-22 Genentech, Inc. Anti-cd3 antibodies and methods of use
FI126633B (en) 2015-07-10 2017-03-15 Next Biomed Therapies Oy Method for the preparation of a library of derivatives of the SH3 domain of recombinant nephrocystin (NPHP1)
KR20190074300A (en) 2016-11-15 2019-06-27 제넨테크, 인크. Dosage for treatment with anti-CD20 / anti-CD3 bispecific antibodies
US10722589B2 (en) * 2017-04-03 2020-07-28 Covagen Ag FGFR3 binding molecules
EP3615571A1 (en) * 2017-04-24 2020-03-04 Ichnos Sciences SA T cell redirecting bispecific antibodies for the treatment of egfr positive cancers
AR111960A1 (en) 2017-05-26 2019-09-04 Incyte Corp CRYSTALLINE FORMS OF A FGFR INHIBITOR AND PROCESSES FOR ITS PREPARATION
EP3664814A4 (en) 2017-08-11 2021-05-05 City of Hope Rna aptamers against transferrin receptor (tfr)
US20200181264A1 (en) * 2017-08-11 2020-06-11 City Of Hope Bispecific antigen-binding molecule
BR112020004543A2 (en) 2017-09-08 2020-09-08 Maverick Therapeutics, Inc. conditionally restricted activated binding proteins
EP3679068A2 (en) * 2017-09-08 2020-07-15 Maverick Therapeutics, Inc. CONDITIONALLY ACTIVATED BINDING MOIETIES CONTAINING Fc REGIONS
US20190100587A1 (en) 2017-10-02 2019-04-04 Covagen Ag IgG1 Fc MUTANTS WITH ABLATED EFFECTOR FUNCTIONS
US20190153096A1 (en) 2017-10-02 2019-05-23 Covagen Ag Cd3/cd33 bispecific binding molecules
CN111712261A (en) 2018-02-08 2020-09-25 豪夫迈·罗氏有限公司 Bispecific antigen binding molecules and methods of use
PE20210920A1 (en) 2018-05-04 2021-05-19 Incyte Corp SOLID FORMS OF A FGFR INHIBITOR AND PROCESSES TO PREPARE THEM
WO2019213506A1 (en) 2018-05-04 2019-11-07 Incyte Corporation Salts of an fgfr inhibitor
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
KR20220100879A (en) 2019-10-14 2022-07-18 인사이트 코포레이션 Bicyclic heterocycles as FGFR inhibitors
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
JP2023505258A (en) 2019-12-04 2023-02-08 インサイト・コーポレイション Tricyclic heterocycles as FGFR inhibitors
PE20221504A1 (en) 2019-12-04 2022-09-30 Incyte Corp DERIVATIVES OF AN FGFR INHIBITOR
EP4073111A1 (en) 2019-12-11 2022-10-19 Cilag GmbH International Multispecific binding molecules comprising ltbr and edb binding domains and uses thereof
US11845799B2 (en) 2019-12-13 2023-12-19 Genentech, Inc. Anti-Ly6G6D antibodies and methods of use
US11939331B2 (en) 2021-06-09 2024-03-26 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors
WO2023044483A2 (en) 2021-09-20 2023-03-23 Voyager Therapeutics, Inc. Compositions and methods for the treatment of her2 positive cancer
WO2023092004A1 (en) 2021-11-17 2023-05-25 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
WO2023201291A1 (en) 2022-04-13 2023-10-19 Genentech, Inc. Pharmaceutical compositions of mosunetuzumab and methods of use
WO2023220695A2 (en) 2022-05-13 2023-11-16 Voyager Therapeutics, Inc. Compositions and methods for the treatment of her2 positive cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1892248A1 (en) * 2006-08-21 2008-02-27 Eidgenössische Technische Hochschule Zürich Specific and high affinity binding proteins comprising modified SH3 domains of FYN kinase
AU2010288542B2 (en) * 2009-08-27 2014-05-22 Covagen Ag IL-17 binding compounds and medical uses thereof
WO2011116387A1 (en) * 2010-03-19 2011-09-22 Tetragenetics, Inc. Production of aglycosylated monoclonal antibodies in ciliates
CA3051311A1 (en) * 2010-05-27 2011-12-01 Genmab A/S Monoclonal antibodies against her2

Also Published As

Publication number Publication date
WO2014170063A1 (en) 2014-10-23
EP2986630A1 (en) 2016-02-24
AU2014256037A1 (en) 2015-10-29
ZA201507752B (en) 2017-03-29
CL2015003085A1 (en) 2016-06-03
JP6694808B2 (en) 2020-05-20
KR20160002882A (en) 2016-01-08
JP2019106997A (en) 2019-07-04
HK1214605A1 (en) 2016-07-29
CN105189544A (en) 2015-12-23
BR112015026143A2 (en) 2017-10-17
JP2016516789A (en) 2016-06-09
CA2908988A1 (en) 2014-10-23
MX2015014608A (en) 2016-03-03
PH12015502278A1 (en) 2016-02-01
EP2986630B1 (en) 2018-08-15
EA201592006A1 (en) 2016-03-31
AU2014256037B2 (en) 2017-09-21

Similar Documents

Publication Publication Date Title
HK1214605A1 (en) Novel bispecific binding molecules with antitumoral activity
IL271102A (en) Bispecific t cell activating antigen binding molecules
HK1218425A1 (en) Bispecific cell activating antigen binding molecules
HK1214275A1 (en) Bispecific-fc molecules fc
HK1223402A1 (en) Immuno-oncolytic therapies
IL246002A0 (en) Novel methods
HK1211299A1 (en) Bispecific cell activating antigen binding molecules
GB201311487D0 (en) Bispecific molecules
AP2015008266A0 (en) 1L-18 binding molecules
IL234234B (en) Ang2-binding molecules
GB201312059D0 (en) Novel GAK modulators
IL235134A0 (en) Il-6 binding molecules
HK1209038A1 (en) Small molecules that promote skin regeneration
IL245048B (en) Mechanical-biological filter
GB201312727D0 (en) Modulators
GB201407008D0 (en) Binders
SG11201509238WA (en) Modified collagen molecules
GB201318298D0 (en) Modulators
GB201317988D0 (en) Modulators
GB201306192D0 (en) Novel methods
GB201222225D0 (en) Smartphone application
GB201314294D0 (en) Binding surfaces
GB201304473D0 (en) Modulators
GB201214493D0 (en) Therapies